Clinical Trials
Medical breakthroughs by the Medically Associated Science and Technology (MAST) program are made possible due to patient participation in clinical trials. Learn more about prolific MAST studies and how patients can become involved in this important work to discover new treatments, improve outcomes and advance patient care.
The purpose of this study is to evaluate the investigational use of a combination of a drug called rifaximin and a dietary supplement, N-acetyl-L-cysteine (NAC), in patients with irritable bowel syndrome with diarrhea (IBS-D).
The purpose of the study is to understand how microorganisms in the gut affect individuals and how they may contribute to gut-related human diseases.
The purpose of this pilot study is to identify the causes of a condition called colonic inertia, which involves severe constipation. Researchers aim to determine whether colonic inertia can be caused by changes in the types of microbes that are present in the colon, or possibly by a toxin produced by particular microbes.
The purpose of this study is to understand the causes of irritable bowel syndrome (IBS) by looking at both genetic and immunologic mechanisms. Examination of DNA will enable researchers to understand which gene(s) contributes to the development of IBS.
The purpose of this study is to find ways to decrease levels of a gas called hydrogen sulfide.
The purpose of this study is to examine how well the antibiotic rifaximin (XifaxanTM) works in patients who have visceral hypersensitivity caused by irritable bowel syndrome with diarrhea (IBS-D) or mixed irritable bowel syndrome (IBS-M).
Have Questions or Need Help?
If you have any questions or want to learn more about Medically Associated Science and Technology (MAST) Program, please give us a call or send us a message.
